Showing 1 - 19 results of 19 for search 'Salomon M Stemmer', query time: 0.06s Refine Results
  1. 1
    Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis

    Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis by Amos Stemmer, Inbal Shafran, Salomon M. Stemmer, Daliah Tsoref

    Published 2020-10-01
    Get full text
    Article
  2. 2
    Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System

    Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System by Noa Gordon, Noa Gordon, Daniel A. Goldstein, Daniel A. Goldstein, Daniel A. Goldstein, Boaz Tadmor, Salomon M. Stemmer, Salomon M. Stemmer, Dan Greenberg

    Published 2021-10-01
    Get full text
    Article
  3. 3
    Proteinoid Polymers and Nanocapsules for Cancer Diagnostics, Therapy and Theranostics: In Vitro and In Vivo Studies

    Proteinoid Polymers and Nanocapsules for Cancer Diagnostics, Therapy and Theranostics: In Vitro and In Vivo Studies by Ella Itzhaki, Yuval Elias, Neta Moskovits, Salomon M. Stemmer, Shlomo Margel

    Published 2023-04-01
    Get full text
    Article
  4. 4
    Factors Affecting Communication Patterns between Oncology Staff and Family Members of Deceased Patients: A Cross-Sectional Study.

    Factors Affecting Communication Patterns between Oncology Staff and Family Members of Deceased Patients: A Cross-Sectional Study. by Tal Granot, Noa Gordon, Shlomit Perry, Shulamith Rizel, Salomon M Stemmer

    Published 2016-01-01
    Get full text
    Article
  5. 5
    Tumor-Targeted Fluorescent Proteinoid Nanocapsules Encapsulating Synergistic Drugs for Personalized Cancer Therapy

    Tumor-Targeted Fluorescent Proteinoid Nanocapsules Encapsulating Synergistic Drugs for Personalized Cancer Therapy by Ella Itzhaki, Elad Hadad, Neta Moskovits, Salomon M. Stemmer, Shlomo Margel

    Published 2021-07-01
    Get full text
    Article
  6. 6
    In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels.

    In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. by Hadas Bar-Joseph, Irit Ben-Aharon, Moran Tzabari, Galia Tsarfaty, Salomon M Stemmer, Ruth Shalgi

    Published 2011-01-01
    Get full text
    Article
  7. 7
    Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside

    Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside by Mattan Levi, Tal Goshen-Lago, Rinat Yerushalmi, Tal Granot, Salomon M. Stemmer, Ruth Shalgi, Irit Ben-Aharon

    Published 2020-12-01
    Get full text
    Article
  8. 8
    LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

    LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial by Talia Golan, Ravit Geva, Donald Richards, Srinivasan Madhusudan, Boris Kin Lin, Haofei Tiffany Wang, Richard A. Walgren, Salomon M. Stemmer

    Published 2018-10-01
    Get full text
    Article
  9. 9
    Doxorubicin-induced vascular toxicity--targeting potential pathways may reduce procoagulant activity.

    Doxorubicin-induced vascular toxicity--targeting potential pathways may reduce procoagulant activity. by Irit Ben Aharon, Hadas Bar Joseph, Moran Tzabari, Boris Shenkman, Nahid Farzam, Mattan Levi, Ruth Shalgi, Salomon M Stemmer, Naphtali Savion

    Published 2013-01-01
    Get full text
    Article
  10. 10
    Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years

    Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years by Erez Bar-Haim, Noa Eliakim-Raz, Amos Stemmer, Hila Cohen, Uri Elia, Asaf Ness, Muhammad Awwad, Nassem Ghantous, Neta Moskovits, Shahar Rotem, Salomon M. Stemmer

    Published 2022-05-01
    Get full text
    Article
  11. 11
    Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.

    Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis. by Rinat Yerushalmi, Hadar Goldvaser, Aaron Sulkes, Irit Ben-Aharon, Daniel Hendler, Victoria Neiman, Noa Beatrice Ciuraru, Luisa Bonilla, Limor Amit, Alona Zer, Tal Granot, Shulamith Rizel, Salomon M Stemmer

    Published 2014-01-01
    Get full text
    Article
  12. 12
    Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma

    Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma by Assaf Moore, Michal Cohen-Naftaly, Anna Tobar, Yulia Kundel, Ofer Benjaminov, Marius Braun, Assaf Issachar, Eytan Mor, Michal Sarfaty, Dimitri Bragilovski, Ran Ben Hur, Noa Gordon, Salomon M. Stemmer, Aaron M. Allen

    Published 2017-10-01
    Get full text
    Article
  13. 13
    Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study

    Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study by Noa Eliakim-Raz, Haim Ben-Zvi, Erez Bar-Haim, Salomon M Stemmer, Amos Stemmer, Yaara Leibovici-Weisman, Asaf Ness, Muhammad Awwad, Nassem Ghantous, Noam Erez, Avital Bareket-Samish, Adva Levy-Barda, Neta Moskovits

    Published 2022-08-01
    Get full text
    Article
  14. 14
    Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry

    Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry by Shlomit S. Shachar, Michelle Leviov, Rinat Yerushalmi, Karen Drumea, Margarita Tokar, Lior Soussan-Gutman, Avital Bareket-Samish, Amir Sonnenblick, Noa Ben-Baruch, Ella Evron, Einav Nili Gal-Yam, Shani Paluch-Shimon, Gil Bar-Sela, Hadar Goldvaser, Salomon M. Stemmer

    Published 2023-09-01
    Get full text
    Article
  15. 15
    High-Resolution Genomic Profiling of Liver Cancer Links Etiology With Mutation and Epigenetic SignaturesSummary

    High-Resolution Genomic Profiling of Liver Cancer Links Etiology With Mutation and Epigenetic SignaturesSummary by Shira Perez, Anat Lavi-Itzkovitz, Moriah Gidoni, Tom Domovitz, Roba Dabour, Ishant Khurana, Ateret Davidovich, Ana Tobar, Alejandro Livoff, Evgeny Solomonov, Yaakov Maman, Assam El-Osta, Yishan Tsai, Ming-Lung Yu, Salomon M. Stemmer, Izhak Haviv, Gur Yaari, Meital Gal-Tanamy

    Published 2023-01-01
    Get full text
    Article
  16. 16
    Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.

    Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. by Shira Perez, Antony Kaspi, Tom Domovitz, Ateret Davidovich, Anat Lavi-Itzkovitz, Tomer Meirson, Jacinta Alison Holmes, Chia-Yen Dai, Chung-Feng Huang, Raymond T Chung, Assy Nimer, Assam El-Osta, Gur Yaari, Salomon M Stemmer, Ming-Lung Yu, Izhak Haviv, Meital Gal-Tanamy

    Published 2019-06-01
    Get full text
    Article
  17. 17
    Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study

    Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study by Ofer Rotem, Idit Peretz, Michelle Leviov, Iryna Kuchuk, Amit Itay, Margarita Tokar, Shani Paluch-Shimon, Ofra Maimon, Rinat Yerushalmi, Karen Drumea, Ella Evron, Amir Sonnenblick, Einav Gal-Yam, Hadar Goldvaser, Yosef Samih, Rotem Merose, Avital Bareket-Samish, Lior Soussan-Gutman, Salomon M. Stemmer

    Published 2023-06-01
    Get full text
    Article
  18. 18
    Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

    Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial by Salomon M. Stemmer, Nebojsa S. Manojlovic, Mihai Vasile Marinca, Petar Petrov, Nelly Cherciu, Doina Ganea, Tudor Eliade Ciuleanu, Ioana Adriana Pusca, Muhammad Shaalan Beg, William T. Purcell, Adina-Emilia Croitoru, Rumyana Nedyalkova Ilieva, Sladjana Natošević, Amedeia Lavinir Nita, Dimitar Nikolaev Kalev, Zivit Harpaz, Motti Farbstein, Michael H. Silverman, David Bristol, Inbal Itzhak, Pnina Fishman

    Published 2021-01-01
    Get full text
    Article
  19. 19
    Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

    Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers by James J. Harding, Sarina A. Piha-Paul, Ronak H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa

    Published 2023-02-01
    Get full text
    Article

Search Tools: